| Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside |
67 |
| The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity |
52 |
| Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment |
50 |
| Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors |
49 |
| Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities |
37 |
| Immunotherapy and Prevention of Pancreatic Cancer |
35 |
| The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer |
32 |
| The Evolving Landscape of Brain Metastasis |
31 |
| Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot' |
30 |
| Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates |
29 |
| Interplay between Circadian Clock and Cancer: New Frontiers for Cancer Treatment |
29 |
| Gluconeogenesis in Cancer: Function and Regulation of PEPCK, FBPase, and G6Pase |
25 |
| Polytherapy and Targeted Cancer Drug Resistance |
23 |
| CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer |
23 |
| Glypicans as Cancer Therapeutic Targets |
20 |
| Glycosylation and Integrin Regulation in Cancer |
19 |
| YAP/TAZ Signaling and Resistance to Cancer Therapy |
19 |
| Nuclear Mechanopathology and Cancer Diagnosis |
19 |
| Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma |
18 |
| Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy |
18 |
| Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection |
17 |
| Metabolic Regulation of Macrophage Polarization in Cancer |
17 |
| Cancer Cachexia: More Than Skeletal Muscle Wasting |
16 |
| Glioblastoma Therapy in the Age of Molecular Medicine |
16 |
| The MYC Enhancer-ome: Long-Range Transcriptional Regulation of MYC in Cancer |
15 |
| MicroRNA-Based Drugs for Brain Tumors |
15 |
| Synthetically Lethal Interactions of ATM, ATR, and DNA-PKcs |
15 |
| Rise of the Machines: Advances in Deep Learning for Cancer Diagnosis |
14 |
| Lipid Metabolism at the Nexus of Diet and Tumor Microenvironment |
14 |
| Bone Metastasis: Find Your Niche and Fit in |
14 |
| Targeting Pancreatic Stellate Cells in Cancer |
14 |
| Deregulation of Retroelements as an Emerging Therapeutic Opportunity in Cancer |
13 |
| Distant Relations: Macrophage Functions in the Metastatic Niche |
13 |
| PRC1: Linking Cytokinesis, Chromosomal Instability, and Cancer Evolution |
13 |
| Noninvasive PET Imaging of T cells |
13 |
| Epigenetic Priming in Cancer Initiation |
12 |
| The Multiple Layers of the Tumor Environment |
12 |
| Gastrointestinal Stromal Tumors: The GIST of Precision Medicine |
12 |
| Fibroblasts Fuel Immune Escape in the Tumor Microenvironment |
12 |
| Unmasking the Many Faces of Tumor-Associated Neutrophils and Macrophages: Considerations for Targeting Innate Immune Cells in Cancer |
12 |
| Synthetic Lethality and Cancer - Penetrance as the Major Barrier |
11 |
| Emerging Contributions of Cancer/Testis Antigens to Neoplastic Behaviors |
11 |
| ADAR and Immune Silencing in Cancer |
11 |
| Deciphering the Epitranscriptome in Cancer |
10 |
| Targetting the Tumor Microenvironment of Leukemia and Lymphoma |
9 |
| Population Dynamics in Cell Death: Mechanisms of Propacation |
9 |
| Dissemination from a Solid Tumor: Examining the Multiple Parallel Pathways |
9 |
| Integrative Approaches to Cancer Immunotherapy |
9 |
| Improving CNS Delivery to Brain Metastases by Blood-Tumor Barrier Disruption |
9 |
| Prostate Luminal Progenitor Cells in Development and Cancer |
9 |
